TokenPost topic
1 TokenPost story is tagged SELLAS. The newest appear first.
Median survival was 24.0 months for patients receiving galinpepimut-S, compared with 14.7 months for the comparison group.
Nov 17, 2026, 9:55 AM EST ยท Investing